Radiology

Blackford and Pixyl Partner to Aid Detection and Monitoring of Neurological Diseases

Retrieved on: 
Thursday, March 14, 2024
Diagnosis, Certification, Brain, MRI, Partnership, Patient, Radiology, Neuro, European, DSM-IV codes, FDA, Health, Medtech, Medical device

Blackford’s tried-and-tested platform solution provides healthcare professionals access to an extensive portfolio of more than 120 AI solutions designed to drive clinical accuracy and efficiency and improve patient outcomes.

Key Points: 
  • Blackford’s tried-and-tested platform solution provides healthcare professionals access to an extensive portfolio of more than 120 AI solutions designed to drive clinical accuracy and efficiency and improve patient outcomes.
  • By integrating Pixyl’s advanced technology into the Blackford Platform, Blackford can offer healthcare providers more powerful tools to support the diagnosis and monitoring of neuroinflammatory and neurodegenerative diseases on MRI.
  • "Pixyl's commitment to the detection and management of neurological diseases is a great fit with our mission to leverage AI to improve the lives of patients and populations," said Ben Panter, Founder and CEO of Blackford.
  • "We are thrilled to partner with Blackford, a proven leader in AI adoption, to ensure that medical professionals can access the most advanced AI solutions and instantly access the information needed to diagnose and treat diseases earlier," notes Senan Doyle, CEO at Pixyl.

Philips and AWS collaborate to scale digital pathology in the cloud, enhancing diagnostic capabilities and improving productivity

Retrieved on: 
Tuesday, March 12, 2024
Cloud, Diagnosis, Informatics, GM, Organization, Health, Radiology, Pathology, Education, PHG, Research, News, Cancer, AI, AWS, Workflow, HIMSS, Amazon Web Services, FMS, AEX, Medical imaging

The collaboration unites Philips’ leadership and expertise in digitization of pathology to optimize clinical workflows and AWS’ leadership in scalable, secure cloud solutions.

Key Points: 
  • The collaboration unites Philips’ leadership and expertise in digitization of pathology to optimize clinical workflows and AWS’ leadership in scalable, secure cloud solutions.
  • Philips and AWS will advance digital pathology and help pathology labs to efficiently store, manage, and analyze growing volumes of digital pathology data and enable more pathology labs to adopt digital workflows to increase productivity.
  • Philips’ collaboration with AWS has the potential to enable large scale clinical trials, multi-institute studies, and care collaboration to address complex cases, including in cancer care.
  • Philips will use AWS HealthImaging to optimize storage, increase scale and enable AI and research across the healthcare system to advance pathology image analysis and simplify clinical workflows.

Cardiawave is presenting the 30-day follow-up results from its “Valvosoft® Pivotal Study” on the treatment of severe symptomatic aortic valve stenosis

Retrieved on: 
Friday, April 5, 2024
Medical Devices, Health, Clinical Trials, Radiology, Cardiology, Biotechnology, Science, FIM, Patient, Journal, Research, Quality of life, American College, Calendar

Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, will present the 30-day follow-up results for 60 patients enrolled in its European pivotal study to the 73rd annual conference of the American College of Cardiology in Atlanta, Georgia.

Key Points: 
  • Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, will present the 30-day follow-up results for 60 patients enrolled in its European pivotal study to the 73rd annual conference of the American College of Cardiology in Atlanta, Georgia.
  • This is a leading event in the cardiovascular medicine calendar, which brings together specialists from around the world to discuss the latest advances, research results and clinical innovations in the field of cardiology.
  • Prof. Eric Van Belle, cardiologist at Lille University Hospital, one of the principal investigators for the European pivotal study, commented: “I’m very proud to present the excellent results obtained using Cardiawave’s NIUT device to treat patients with severe symptomatic aortic valve stenosis, leading to a significant improvement in their condition and a better quality of life.
  • Time and date: April 8, 2024 - 9:32 a.m.–9:42 a.m. EDT
    The results of the Cardiawave First-in-Human “Valvosoft® FIM Study” were published in The Lancet in November 2023:

RLS Radiopharmacies Partners with Eckert & Ziegler to Expand Production of Gallium-68-Based Radiopharmaceuticals

Retrieved on: 
Thursday, April 4, 2024
Oncology, Medical Devices, Health, Radiology, Pharmaceutical, Biotechnology, Gallium, Diagnosis, Radionuclide, Glomus tumor, Prostate cancer, USP, Half-life, Actinium-225, Partnership, Patient, Pharmacy, RLS, PET, Splenic infarction, Cancer, SDAX, Radiopharmaceutical, Investment, Cyclotron, ISO, Positron emission tomography, DSM-IV codes, Gelastic seizure, Medical imaging

Under the partnership, all 31 of RLS’s radiopharmacies will be equipped with Eckert & Ziegler’s advanced GalliaPharm® generators, which the radiopharmacy network will utilize to produce high-quality, life-enhancing Gallium-68-based (Ga-68) radiopharmaceuticals.

Key Points: 
  • Under the partnership, all 31 of RLS’s radiopharmacies will be equipped with Eckert & Ziegler’s advanced GalliaPharm® generators, which the radiopharmacy network will utilize to produce high-quality, life-enhancing Gallium-68-based (Ga-68) radiopharmaceuticals.
  • “A powerful diagnostic isotope, Gallium has an extremely short half-life, necessitating the need for Ga-68-based radiopharmaceuticals to be produced within minutes of patient dosing.
  • This signifies a major leap forward in our commitment to advancing healthcare and improving patient outcomes through cutting-edge radiopharmaceuticals."
  • To date, RLS has installed Eckert & Ziegler’s GalliaPharm® generators within most of its locations and anticipates the remaining radiopharmacies will be operational by the end of June.

NorthStar Medical Radioisotopes Announces Participation in Upcoming 2024 Jefferies Radiopharma Innovation Summit

Retrieved on: 
Thursday, April 4, 2024
Oncology, Health, Hospitals, Health Technology, Radiology, Pharmaceutical, Biotechnology, Jefferies, Actinium-225, Radiopharmaceutical, Therapy, Cancer, NorthStar, CDMO, PET, Growth, Medical imaging

NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production, and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced that Frank Scholz, Ph.D., President and Chief Executive Officer will present at the upcoming 2024 Jefferies Radiopharma Innovation Summit.

Key Points: 
  • NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production, and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced that Frank Scholz, Ph.D., President and Chief Executive Officer will present at the upcoming 2024 Jefferies Radiopharma Innovation Summit.
  • “2024 and the next several years are pivotal for NorthStar as we expand our capabilities in the rapidly growing radiopharmaceuticals industry,” said Frank Scholz, Ph.D., President and Chief Executive Officer of NorthStar Medical Radioisotopes.
  • Our radiopharmaceutical R&D lab is busy with both PET diagnostics and therapeutics work where sponsors are experiencing useful results as they work to improve upon their formulations and processes.
  • Please reach out to your Jefferies representative to schedule.

Velsera and Flywheel Team up to Support Multimodal Imaging Genomics Research

Retrieved on: 
Thursday, April 4, 2024
Other Health, General Health, Radiology, Pharmaceutical, Medical Devices, Technology, Hospitals, Artificial Intelligence, Genetics, Health Technology, Biotechnology, Health, Genomics, Algorithm, MRI, FHIR, Down syndrome, Environment, Investigation, Disease, Patient, Artificial intelligence, AI, PB, NIH, Ecosystem, Privacy, Government, Syndrome, Metadata, Medical imaging

Combining their capabilities, Velsera, Flywheel, and D3b were able to manage, harmonize, and analyze large datasets in a cloud-based platform.

Key Points: 
  • Combining their capabilities, Velsera, Flywheel, and D3b were able to manage, harmonize, and analyze large datasets in a cloud-based platform.
  • The Velsera team created interoperability standards that allow platforms to communicate with each other and make large-scale data access transparent to the user.
  • “Linking our Flywheel Core Platform with Velsera’s CAVATICA platform facilitates an unparalleled ability to perform advanced, multimodal data analysis in a cloud environment,” said Travis Richardson, Chief Strategist at Flywheel.
  • Using data from D3b, teams were able to analyze the combination of extracted imaging features on the Flywheel Core Platform.

Global Mobile Medical Imaging Market Trends and Growth Analysis Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 4, 2024
Radiology, Health, Medical Devices, Row, COVID-19, Privacy, Computer security, Telehealth, POC, Medical device

The "Global Mobile Medical Imaging Market Trends and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Mobile Medical Imaging Market Trends and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • The report focuses on mobile imaging equipment for POC settings, enabling bedside imaging and remote diagnosis (excluding conventional, trailer-mounted mobile imaging equipment that users must transport to different locations).
  • There is a growing demand for mobile imaging equipment in low and middle-income countries due to the limited financial resources to procure, operate, and maintain expensive medical imaging equipment.
  • This study will provide the trends, challenges, drivers, restraints, competitive landscape, and growth opportunities for mobile medical imaging systems in different clinical settings, including at-home medical imaging and remote diagnosis.

Gennao Bio Announces Upcoming Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Thursday, April 4, 2024
Oncology, Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Neoplasm, Radiology, AACR, Yale school, Therapy, ADC, Vaccine

Gennao Bio , a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced that an abstract reporting preclinical results of its non-viral, cell penetrating gene monoclonal antibody (GMAB) platform technology has been selected for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5 – 10, 2024 in San Diego, CA.

Key Points: 
  • Gennao Bio , a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced that an abstract reporting preclinical results of its non-viral, cell penetrating gene monoclonal antibody (GMAB) platform technology has been selected for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5 – 10, 2024 in San Diego, CA.
  • The poster presentation will showcase exploratory research conducted through Gennao’s ongoing collaboration with the laboratory of Peter M. Glazer, M.D., Ph.D., Chair of the Department of Therapeutic Radiology, Professor of Genetics and Robert E. Hunter Professor of Therapeutic Radiology at the Yale School of Medicine.
  • Specifically, the presentation will demonstrate the potential application of the GMAB platform as an antibody-drug conjugate (ADC) for the treatment of solid tumors.
  • The details of the poster presentation are as follows:
    Title: Targeted delivery of Exatecan to tumors via a novel cell-penetrating, anti-DNA antibody

Nimble Therapeutics Expands its Drug Discovery Capabilities to Advance Pipeline to the Clinic

Retrieved on: 
Wednesday, April 3, 2024
Oncology, Health, Infectious Diseases, Radiology, Pharmaceutical, Biotechnology, Pfizer, De Montfort University, Drug discovery, Yale University, BU, Harvard University, Patient, Flavell, Immunology, Merck, Head, Wetzler, Merck & Co., IND, Rhône-Poulenc, Therapy, CSO, American Chemical Society, Medicinal chemistry, Peptide, Pharmaceutical industry

In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.

Key Points: 
  • In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.
  • Shelley Allen will join as Head of Drug Discovery and will lead the advanced optimization and characterization of clinical candidate peptides and their progression into the clinic.
  • Munir Mosaheb will join as Head of Biology and will lead the pharmacological, immunological and translational aspects of Nimble’s drug discovery programs.
  • She joined Nimble from Think Bioscience where she was VP, Medicinal Chemistry, and responsible for establishing drug discovery teams and capabilities to develop their internal programs.

Geneoscopy to Present Research on Inflammatory Bowel Disease at Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference

Retrieved on: 
Wednesday, April 3, 2024
Managed Care, Research, Radiology, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Genetics, Health Technology, Science, Biotechnology, Health, Other Science, Conference, Medicine, Patient, UC, RNA, IBD, Inflammatory bowel disease, Ulcerative colitis, Therapy, Pharmaceutical industry

Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, will present research at the Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference in Cambridge, Mass., April 9-10.

Key Points: 
  • Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, will present research at the Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference in Cambridge, Mass., April 9-10.
  • The data showcases the potential predictive capabilities of Geneoscopy’s noninvasive stool RNA biomarker technology in informing therapeutic response for patients with inflammatory bowel disease (IBD).
  • Our participation at IBD Innovate reaffirms our commitment to advancing precision immunology for patients with IBD."
  • The research examined stool-derived eukaryotic RNA (seRNA) to predict therapeutic response and disease activity in Crohn’s Disease (CD) and Ulcerative Colitis (UC).